These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1136 related articles for article (PubMed ID: 8746340)

  • 1. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma.
    Wang YL; Uhara H; Yamazaki Y; Nikaido T; Saida T
    Br J Dermatol; 1996 Feb; 134(2):269-75. PubMed ID: 8746340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The p16-cyclin D/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis.
    Bartkova J; Lukas J; Guldberg P; Alsner J; Kirkin AF; Zeuthen J; Bartek J
    Cancer Res; 1996 Dec; 56(23):5475-83. PubMed ID: 8968104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations associated with familial melanoma impair p16INK4 function.
    Ranade K; Hussussian CJ; Sikorski RS; Varmus HE; Goldstein AM; Tucker MA; Serrano M; Hannon GJ; Beach D; Dracopoli NC
    Nat Genet; 1995 May; 10(1):114-6. PubMed ID: 7647780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines.
    He J; Olson JJ; James CD
    Cancer Res; 1995 Nov; 55(21):4833-6. PubMed ID: 7585516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer-associated mis-sense and deletion mutations impair p16INK4 CDK inhibitory activity.
    Lilischkis R; Sarcevic B; Kennedy C; Warlters A; Sutherland RL
    Int J Cancer; 1996 Apr; 66(2):249-54. PubMed ID: 8603820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma.
    Ohta M; Nagai H; Shimizu M; Rasio D; Berd D; Mastrangelo M; Singh AD; Shields JA; Shields CL; Croce CM
    Cancer Res; 1994 Oct; 54(20):5269-72. PubMed ID: 7923152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas.
    Bachmann IM; Straume O; Akslen LA
    Int J Oncol; 2004 Dec; 25(6):1559-65. PubMed ID: 15547691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions.
    Keller-Melchior R; Schmidt R; Piepkorn M
    J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inducible nitric oxide synthase expression in benign and malignant cutaneous melanocytic lesions.
    Massi D; Franchi A; Sardi I; Magnelli L; Paglierani M; Borgognoni L; Maria Reali U; Santucci M
    J Pathol; 2001 Jun; 194(2):194-200. PubMed ID: 11400148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous loss of the p15INK4B gene (and not the p16INK4 gene) during tumor progression in a sporadic melanoma patient.
    Glendening JM; Flores JF; Walker GJ; Stone S; Albino AP; Fountain JW
    Cancer Res; 1995 Dec; 55(23):5531-5. PubMed ID: 7585628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
    Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
    Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers.
    Nobori T; Miura K; Wu DJ; Lois A; Takabayashi K; Carson DA
    Nature; 1994 Apr; 368(6473):753-6. PubMed ID: 8152487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16 proteins from melanoma-prone families are deficient in binding to Cdk4.
    Reymond A; Brent R
    Oncogene; 1995 Sep; 11(6):1173-8. PubMed ID: 7566978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of the sun on expression of beta-catenin, p16 and cyclin d1 proteins in melanocytic lesions.
    Demirkan NC; Kesen Z; Akdag B; Larue L; Delmas V
    Clin Exp Dermatol; 2007 Nov; 32(6):733-9. PubMed ID: 17868395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression and cell cycle regulation of the cyclin-dependent kinase 4 inhibitor p16Ink4.
    Tam SW; Shay JW; Pagano M
    Cancer Res; 1994 Nov; 54(22):5816-20. PubMed ID: 7954407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16/CDKN2 and CDK4 gene mutations in sporadic melanoma development and progression.
    Piccinin S; Doglioni C; Maestro R; Vukosavljevic T; Gasparotto D; D'Orazi C; Boiocchi M
    Int J Cancer; 1997 Feb; 74(1):26-30. PubMed ID: 9036865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines.
    Della Ragione F; Russo G; Oliva A; Mastropietro S; Mancini A; Borrelli A; Casero RA; Iolascon A; Zappia V
    Oncogene; 1995 Mar; 10(5):827-33. PubMed ID: 7898924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB.
    Otterson GA; Kratzke RA; Coxon A; Kim YW; Kaye FJ
    Oncogene; 1994 Nov; 9(11):3375-8. PubMed ID: 7936665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.